Why the study?
Real-world evidence was needed regarding the impact of IV ferric carboxymaltose on arrhythmic burden in patients with HFrEF, iron deficiency, and CIEDs.
Does intravenous ferric carboxymaltose improve iron parameters and reduce arrhythmic burden in adult patients with HFrEF, iron deficiency, and CIEDs?
Does intravenous ferric carboxymaltose improve iron parameters and reduce arrhythmic burden in adult patients with HFrEF, iron deficiency, and CIEDs?
The RESAFE-HF registry will evaluate the impact of intravenous ferric carboxymaltose on arrhythmic burden in HFrEF patients with iron deficiency, who demonstrate a high baseline prevalence of ventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
IV FCM was associated with reduced ventricular arrhythmias in HFrEF with ID and CIEDs; leaves open need for RCTs before practice change.
Aims The Iron Intravenous Therapy in Reducing the burden of Severe Arrhythmias in HFrEF (RESAFE-HF) registry study aims to provide real-word evidence on the impact of intravenous ferric carboxymaltose (FCM) on the arrhythmic burden of patients with heart failure with reduced ejection fraction (HFrEF), iron deficiency (ID), and implanted cardiac implantable electronic devices (CIEDs). Methods and results The RESAFE-HF (NCT04974021) study was designed as a prospective, single-centre, and open-label registry study with baseline, 3, 6, and 12 month visits. Adult patients with HFrEF and CIEDs scheduled to receive IV FCM as treatment for ID as part of clinical practice were eligible to participate. The primary endpoint is the composite iron-related endpoint of haemoglobin ≥ 12 g/dL, ferritin ≥ 50 ng/L, and transferrin saturation > 20%. Secondary endpoints include unplanned HF-related hospitalizations, ventricular tachyarrhythmias detected by CIEDs and Holter monitors, echocardiographic markers, functional status (VO2 max and 6 min walk test), blood biomarkers, and quality of life. In total, 106 patients with a median age of 72 years (14.4) were included. The majority were male (84.9%), whereas 92.5% of patients were categorized to New York Heart Association II/III. Patients' arrhythmic burden prior to FCM administration was significant—19 patients (17.9%) received appropriate CIED therapy for termination of ventricular tachyarrhythmia in the preceding 12 months, and 75.5% of patients have frequent, repetitive multiform premature ventricular contractions. Conclusions The RESAFE-HF trial is expected to provide evidence on the effect of treating ID with FCM in HFrEF based on real-world data. Special focus will be given on the arrhythmic burden post-FCM administration.
No takes yet. Share an insight, caveat, or question.
Bakogiannis et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: